Cellectis (CLLS) Total Current Liabilities (2014 - 2026)
Cellectis (CLLS) recorded quarterly Total Current Liabilities of $134.5 million in Q1 2026, down 7.72% quarter-over-quarter from $145.8 million in Q4 2025, and down 17.27% on a YoY basis from $162.6 million in Q1 2025.
Cellectis (CLLS) Total Current Liabilities (2014 - 2026) Analysis & Trends
Cellectis' Total Current Liabilities history runs 13 years deep, the most recent figure standing at $134.5 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 17.27% year-over-year to $134.5 million; the TTM figure through Mar 2026 stood at $134.5 million (down 17.27% YoY), while the FY2025 annual figure was $145.8 million, down 12.34% from the prior year.
- Total Current Liabilities was $134.5 million for Q1 2026 at Cellectis, down from $145.8 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $167.4 million in Q2 2025 to a low of $42.0 million in Q2 2023.
- Historically, Total Current Liabilities has averaged $111.9 million across 5 years, with a median of $145.8 million in 2025.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities dropped 23.94% in 2023, then jumped 279.65% in 2024.
- A 5-year view of Total Current Liabilities shows it stood at $48.1 million in 2022, then soared by 222.34% to $155.1 million in 2023, then gained by 7.17% to $166.3 million in 2024, then decreased by 12.34% to $145.8 million in 2025, then slipped by 7.72% to $134.5 million in 2026.
- The last three Total Current Liabilities figures came in at $134.5 million (Q1 2026), $145.8 million (Q4 2025), and $148.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 13.42 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 72.86 Mn |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | 134.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 134.50 Mn |
| Dec 31, 2025 | 145.75 Mn |
| Sep 30, 2025 | 148.58 Mn |
| Jun 30, 2025 | 167.43 Mn |
| Mar 31, 2025 | 162.57 Mn |
| Dec 31, 2024 | 166.27 Mn |
| Sep 30, 2024 | 165.65 Mn |
| Jun 30, 2024 | 159.63 Mn |
| Mar 31, 2024 | 158.45 Mn |
| Dec 31, 2023 | 155.14 Mn |
| Sep 30, 2023 | 43.95 Mn |
| Jun 30, 2023 | 42.05 Mn |
| Mar 31, 2023 | 43.14 Mn |
| Dec 31, 2022 | 48.13 Mn |
| Sep 30, 2022 | 53.03 Mn |
| Jun 30, 2022 | 55.28 Mn |
| Mar 31, 2022 | 52.34 Mn |
| Dec 31, 2021 | 49.35 Mn |
| Sep 30, 2021 | 49.60 Mn |
| Jun 30, 2021 | 51.45 Mn |